Thirty patients with bronchogenic carcinoma were treated with an 8–week induction therapy consisting of cyclophosphamide, methotrexate, vincristine and VP 16–213 (NSC 141 540). Those who achieved objective remission or tumor stabilization were then placed on an intermittent treatment schedule with the same drugs. Of the 30 patients, 17 had an objective response, 5 remained without change, and 8 progressed. Responses were more frequent among anaplastic (13/19) than epidermoid or adenocarcinoma (4/11). The toxicity consisted mainly of leucopenia, thrombopenia, alopecia, nausea and vomiting. The implications of these findings in the planning of further chemotherapeutic programs are discussed.
Get full access to this article
View all access options for this article.
References
1.
AisnerJ., EsterayR. J., WiernikP. H.: Treatment of oat-cell carcinoma of the lung with cyclophosphamide, adriamycin, epipodophyllotoxin VP 16–213 and methanol extracted residue (MER) of BCG. Proc. ASCO, p. 261, C-98, 1976.
2.
AlbertoP.: Remission rates, survival and prognostic factors in combination chemotherapy for bronchogenic carcinoma. Cancer Chemother. Rep., Part. 3, vol.4: 199–206, 1973.
3.
AlbertoP., BarreletL., ChapuisB., GarciaB.: A combination of adriamycin, CCNU and hydroxyurea in the treatment of disseminated bronchogenic carcinoma. Europ. J. Cancer, 11: 795–799, 1975.
4.
BrunnerK. W., SonntagR. W., RysselH. J., CavalliF.: 4’-Demethylepipodophyllotoxin 9-(4,6-o-dethylidene-B-D-glucopyranoside) (NSC 141 540; VP 16–213): a comparison of the biologic activity when given intravenously and orally as capsules or drink ampules. Cancer Treat. Rep., 60: 1377–1379, 1976.
5.
DombernowskyP., HansenH. H., NissenN. I.: Treatment of small cell anaplastic carcinoma of the lung with an oral solution of VP 16–213 (NSC 141 540). Proc. AACR, p. 129, 515, 1976.
6.
DombernowskyP., NissenN. I.: Combination chemotherapy with 4’-Demethylepipodophyllotoxin 9-(4.6-o-ethylidene-B-D-glucopyranoside) VP 16–213 (NSC 141 540) in L 1210 leukemia. Europ. J. Cancer, 12: 181–188, 1976.
7.
EaganR. T., FrytayS., RubinJ.: VP 16–213 vs polychemotherapy in small cell lung cancer. Proc. ASCO, p. 243, C-25, 1976.
8.
JungiW. F., SennH. J.: Clinical study of the new podophyllotoxinderivative 4’-Demethylepipodophyllotoxin 9-(4,6-o-ethylidene-B-D-glucopyranoside) (NSC 141 540; VP 16–213) in solid tumor in man. Cancer Chemother. Rep., 59: 737–742, 1975.
9.
KreybergL., LiebowA. A., BehlingerE. A.: Histological typing of lung tumors.World Health Organization, Geneva, 1967.
10.
NissenN. I., HansenH. H., PedersenH., StrøyerI., DombernowskyP., HessellundM.: Clinical trial of the oral form of a new podophyllotoxin-derivative, VP 16–213 (NSC 141 540) in patients with advanced neoplastic disease. Cancer Chemother. Rep., 59: 1027–1029, 1975.
11.
RozencweigM., KenisY.: European studies with adriamycin (NSC 123 127) in lung cancer. Cancer Chemother. Rep., Part. 3, Vol.6: 343–347, 1975.
